Pancreatic Ductal Adenocarcinoma — Trials

Pancreatic Ductal Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

414 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 208
Recruiting: 129
Ph III recruiting: 13
Growth YoY: +56.5%
Industry share: 50%
Top sponsor: Revolution Medicines, Inc.
Termination share: 46.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (56)

clinicaltrialsPublishedShowing 301–350 of 414 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03970252	Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer	completed	Early Phase 1	28	Jonsson Comprehensive Cancer CenterOTHER	1	Aug 9, 2024	clinicaltrials
NCT06276803	The LINFU® U.S. Registry for the in the General Population Without Risk Factors	not yet recruiting	—	500	Adenocyte, LLCINDUSTRY	0	Jul 31, 2024	clinicaltrials